76
Participants
Start Date
April 21, 2024
Primary Completion Date
July 7, 2026
Study Completion Date
July 7, 2027
Osimertinib
80 mg daily (or 40 mg daily for dose reduction)
Cisplatin or Carboplatin; Pemetrexed or Paclitaxel
Pemetrexed (500 mg/m2 to be administered on Day 1 of every 3-week cycle for 2 cycles) or Paclitaxel (175 mg/m2 on Day 1 of every 3-week cycle for 2 cycles) PLUS Cisplatin (75 mg/m2) or Carboplatin (AUC5) to be administered on Day 1 of every 3--week cycle for 2 cycles
Radiation
"Patients must have received a total dose of radiation of 60 Gy ± 10% (54 to 66 Gy) as part of the chemoradiation therapy. It is recommended but not required that patients have a:~* Mean lung dose \< 20 Gy and/or V20 \< 35%~* Mean oesophagus dose \< 34 Gy~* Heart V50 \< 25%, V30 \< 50%, and V45 \< 35%"
Research Site, Hanoi
Research Site, Tainan City
Research Site, Bangkok
Research Site, Bangkok
Research Site, Taipei
Research Site, Seongnam-si
Research Site, Suwon
Research Site, Granada
Research Site, Donostia / San Sebastian
Research Site, Madrid
Research Site, Cheongju-si
Research Site, Haifa
Research Site, Khon Kaen
Research Site, Chiang Rai
Research Site, Tel Aviv
Research Site, Hat Yai
Research Site, Jerusalem
Research Site, La Jolla
Research Site, Palo Alto
Research Site, Hanoi
Research Site, Beijing
Research Site, Harbin
Research Site, Shanghai
Research Site, Hefei
Research Site, Jinan
Research Site, Tianjin
Research Site, Hangzhou
Research Site, Changsha
Research Site, Wuhan
Research Site, Wuhan
Research Site, Zhengzhou
Research Site, Guangzhou
Research Site, Nanning
Research Site, Ho Chi Minh City
Research Site, Seoul
Research Site, Seoul
Research Site, Seoul
Research Site, Barcelona
Research Site, Ankara
Research Site, Yenimahalle
Lead Sponsor
AstraZeneca
INDUSTRY